Genmab — Juli 2020
-
God morgen.

-
I this tells it all “There are no therapeutic strategies identified to mitigate the ocular toxicity with belantamab mafodotin,” FDA staff wrote, adding, “Despite implementing dose modifications, ocular toxicities were recurrent and persistent.” Its no competitor to dara.
-
Jeg syntes nu ikke at dansk pharma/biotek ser speciel stærk ud i dag.
-
Klarussen..Jeg tænker generelt - ikke kun på Genmab. Bava er rigtigt nok stærk. Dem der handler meget på teknik føler at de har medvind i aktien pt.
-
PS: Har lavet podcast med Per Hansen i et par timer. Det hjalp åbenbart på kurserne i pharma.

-
Jeps.. man skal ikke ryste på hånden i disse dage...rutsjebanen kører for fuld fart.
-
Som Vitus skrev tidligere bliver det interessant hvad Q2 regnskaberne vil betyde for volatilitet i markedet.
-
nohope..Vi nappede lige en mere. Den steg kursen videre op på.

Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind